gabapentin treatment

PreclinicalSmall molecule

gabapentin treatment is one of 4 small molecule programs targeting Lumbar Spinal Stenosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lumbar Spinal StenosisActive, not recruiting

Lumbar Spinal StenosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Lumbar Spinal Stenosis

#DrugCompanyPhaseTrials

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Limaprost

SSeoul National University Hospital

Approved

1 3

Epidural Steroid

VVertos Medical, Inc.

Preclinical

1 4

gabapentin treatment

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lumbar Spinal Stenosis1 trial

Effect of Baclofen Treatment on Nocturnal Muscle Cramps in Patients With Lumbar Spinal Stenosis: a Randomized Clinical Trial

Completed·YYonsei University·N/A·NCT05392361·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gabapentin treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gabapentin treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gabapentin treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

gabapentin treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lumbar Spinal Stenosis1 trial

References

Drug Info

Quick Facts

Related News